CompletedNCT04181736
Biomarker-Guided Support for Cognitive Difficulties in Depression
About this title
Read the official source — NCT04181736Medication studyAges 18–69United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 69 years.
- Listed locations
- Palo AltoSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: September 14, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 28
- Sponsor
- Stanford University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 69 Years
- Official registry ID
- NCT04181736
- Official title
Show the full official title
Precision Mental Health: Evaluating Biotype-guided Interventions for Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Palo Alto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Stanford University, a university.
Did this study involve medication?
Yes. The study involved medication, including Guanfacine Tablets.
Who was this study for?
Listed age limits: 18 years to 69 years.
